One quarter of persons with adenocarcinoma of the lung develop brain metastases. The central nervous system is also emerging as a major site of first relapse after initial success with drugs targeting EGFR. Despite treatment, two thirds of patients with cerebral metastases experience neurological symptoms and many succumb to this manifestation of lung cancer. Animal model systems of brain metastasis are few. As a result, little is known about the genes and functions that enable lung adenocarcinomacells to colonize the brain. We have combined the power of unbiased DNA array-based profiling of gene expression with in vivo functional selection of organ-specific metastatic cells to identify genes that mediate organ-specific metastasis. We previously validated this experimental strategy in studies on breast cancer metastasis to bone and lung. Our results to date show that tumor cells utilize different sets of genes to colonize different organs. We are applying this approach to the problem of brain metastasis by lung adenocarcinoma cells. By means of in vivo selection of brain metastatic subpopulations from H2030 lung adenocarcinoma cells, and comparative transcriptomic analysis, we have identified a lung-to-brain metastasis signature consisting of genes whose expression is linked to brain metastatic behavior. Building on this preliminary work, we will expand the identification of brain-specific lung cancer metastasis genes to other KRAS mutant and EGFR mutant cell lines, and to malignant cells from pleural effusions and mediastinal lymph nodes from MSKCC patients. We will functionally validate brain-specific metastasis genes in brain metastasis assays in mice. In collaboration with Marc Ladanyi (Core A), we will determine the association of the experimental lung-to-brain metastasis signature with the clinical outcome of brain metastasis. We will determine which of the lung-to- brain metastasis signature genes mediate disruption of the blood brain barrier and invasion of the brain parenchyma. Based on these cell lines and genes we will develop preclinical models for testing the effectiveness of, and resistance to, the therapeutic agents studied by Harold Varmus (RP4), William Pao (RP3), and Neal Rosen (RP2). Thus, we will combine unique experimental approaches, novel technologies and complementary collaborations within this Program Project to identify the determinants of lung adenocarcinoma brain metastasis and its susceptibility to therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA129243-02
Application #
7645147
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
2
Fiscal Year
2008
Total Cost
$349,731
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Yu, Helena A; Planchard, David; Lovly, Christine M (2018) Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book :726-739
Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel et al. (2018) Differential Effector Engagement by Oncogenic KRAS. Cell Rep 22:1889-1902
Ruscetti, Marcus; Leibold, Josef; Bott, Matthew J et al. (2018) NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 362:1416-1422
Du, Zhenfang; Lovly, Christine M (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17:58
Yu, Helena A; Suzawa, Ken; Jordan, Emmet et al. (2018) Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clin Cancer Res 24:3108-3118
Westover, D; Zugazagoitia, J; Cho, B C et al. (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 29:i10-i19
Li, Bob T; Shen, Ronglai; Buonocore, Darren et al. (2018) Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. J Clin Oncol 36:2532-2537
Fan, Pang-Dian; Narzisi, Giuseppe; Jayaprakash, Anitha D et al. (2018) YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci U S A 115:E6030-E6038
Mo, Qianxing; Shen, Ronglai; Guo, Cui et al. (2018) A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics 19:71-86
Childress, Merrida A; Himmelberg, Stephen M; Chen, Huiqin et al. (2018) ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Mol Cancer Res 16:1724-1736

Showing the most recent 10 out of 188 publications